계명대학교 의학도서관 Repository

Subcutaneous Immunotherapy for Allergic Asthma in a Single Center of Korea: Efficacy, Safety, and Clinical Response Predictors

Metadata Downloads
Author(s)
Ji-Ho LeeSu-Chin KimHyunna ChoiChang-Gyu JungGa-Young BanYoo Seob ShinDong-Ho NahmHae-Sim ParkYoung-Min Ye
Keimyung Author(s)
Jung, Chang Gyu
Department
Dept. of Internal Medicine (내과학)
Journal Title
Journal of Korean Medical Science
Issued Date
2017
Volume
32
Issue
7
Keyword
Allergen-Specific ImmunotherapyAllergic AsthmaHouse Dust MitesRemission
Abstract
Allergen-specific immunotherapy is the only causal treatment for allergic diseases. However, the efficacy of immunotherapy may vary around the world due to differences in climate, the nature of aero-allergens and their distribution. The aim of this study was to describe the effects of subcutaneous immunotherapy (SCIT) in Korean adults with allergic asthma (AA). As a retrospective cohort study, we reviewed medical records for 627 patients with AA in Korea who were sensitized to house dust mite (HDM) and/or pollens and who underwent SCIT with aluminum hydroxide adsorbed allergen extract from 2000 to 2012. Rates of remission, defined as no further requirement of maintenance medication, over time were determined by means of life tables and extension of survival analysis. Herein, 627 asthmatic patients achieved remission within a mean of 4.7 ± 0.2 years. The cumulative incidence rates of remission from AA were 86.9% upon treatment with SCIT. Baseline forced expiratory volume in the first second (FEV1) ≥ 80% (hazard ratio [HR], 3.10; 95% confidence interval [CI], 1.79-5.39; P < 0.001), and maintenance of immunotherapy for more than 3 years (HR, 1.82; 95% CI, 1.21-2.72; P = 0.004) were significant predictors of asthma remission during SCIT. In 284 patients on SCIT with HDM alone, initial specific immunoglobulin E (IgE) levels to Dermatophagoides pteronyssinus and Dermatophagoides farinae did not show significant difference between remission and non-remission group after adjusting demographic variables. In conclusion, SCIT was effective and safe treatment modality for patients with AA. Initial FEV1 ≥ 80% and immunotherapy more than 3 years were found to be associated with favorable clinical responses to SCIT.
Keimyung Author(s)(Kor)
정창규
Publisher
School of Medicine (의과대학)
Citation
Ji-Ho Lee et al. (2017). Subcutaneous Immunotherapy for Allergic Asthma in a Single Center of Korea: Efficacy, Safety, and Clinical Response Predictors. Journal of Korean Medical Science, 32(7), 1124–1130. doi: 10.3346/jkms.2017.32.7.1124
Type
Article
ISSN
1011-8934
DOI
10.3346/jkms.2017.32.7.1124
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/41487
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.